GoldenGolden
Amgen

Amgen

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company founded in 1980 with headquarters in Thousand Oaks, California.

Amgen works in discovery, development and manufacturing of human therapeutics for treatment of illnesses in the areas of oncology, hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

Products

Amgen’s products include the following: Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine)and Aimovig.

The top protein-based therapeutics include Neulasta, Neupogen, Aranesp, Epogen and Enbrel. ENBREL is on the market in the United States to treat rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. Neulasta treats people receiving chemotherapy to reduce infection. Aranesp and EPOGEN are used to treat anemia in different circumstances including chronic kidney disease. Cinacalcet (Sensipar in US and Mimpara in Europe) is used for secondary hyperparathyroidism with chronic kidney disease. XGEVA is for prevention of skeletal related events in patients with bone metastases from solid tumors. Prolia is used to treat postmenopausal women with osteoporosis at risk of fracture . NEUPOGEN is a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF) to reduce chance of infection due to low white blood cell count for cancer patients receiving chemotherapy . Aimovig was FDA approved in 2018 and will be marketed in partnership with Novartis as a drug to prevent migraines .

Clinical Trials

The following Amgen therapeutics are candidates in Phase III clinical trials: Erenumab for episodic migraine; Aranesp for myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for psoriatic arthritis and rheumatoid arthritis remission; IMLYGIC for metastatic melanoma; Kyprolis for multiple myeloma; Prolia for glucocorticoid-induced osteoporosis; Repatha for hyperlipidemia; XGEVA for delay or prevention of bone metastases in breast cancer and also for the treatment of cancer-related bone damage in patients with multiple myeloma; Vectibix for metastatic colorectal cancer (mCRC); Omecamtiv mecarbil for chronic heart failure, and EVENITY for postmenopausal osteoporosis and male osteoporosis.

The following Amgen therapeutics are candidates in Phase II clinical trials: BLINCYTO for diffuse Large B-Cell Lymphoma (DLBCL) and relapsed/refractory Philadelphia positive (R/R Ph+) and minimal residual disease of ALL; Erenumab for Chronic migraine; AMG 157 for asthma and atopic dermatitis; AMG 520 for Alzheimer's disease, and AMG 899 for dyslipidemia.

The following Amgen therapeutics are candidates in Phase I clinical trials: IMLYGIC for various cancer types; KYPROLIS for small-cell lung cancer; Oprozomib for multiple myeloma; AMG 176 for various cancer types; AMG 211 for various cancer types; AMG 224 for multiple myeloma, and AMG 301 for migraine. The Company's product candidates in Phase I also include AMG 330 for acute myeloid leukemia; AMG 420 for multiple myeloma; AMG 557 for systemic lupus erythematosus; AMG 570 for systemic lupus erythematosus; AMG 592 for inflammatory diseases; AMG 820 for various cancer types, and AMG 986 for heart failure.

Autoimmune disease

The approved drug Otezla (apremilast), acquired from Celgene in 2019, is a notable therapeutic in Amgen’s autoimmune portfolio. Otezla is for treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis.

Amgen is partnered with EVOQ Therapeutics for license and collaboration to discover and develop drugs for autoimmune disorders.

Timeline

December 22, 2020
Amgen and Medicines Development for Global Health (MDGH) announces that the companies have entered into a license agreement for AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor being investigated for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy.
November 23, 2020
Amgen announces it has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.

November 9, 2020
Amgen and AstraZeneca announce positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe asthma.

2019
Amgen acquires AMG 634 (formerly CC-11050) as part of its acquisition of Otezla® (apremilast) from Celgene.

Funded Companies

Company
Description
Industry
Website
Location
PTC Therapeutics

A biopharmaceutical company focused on discovery and development of small-molecule drugs to treat genetic and rare diseases

miRagen is a clinical stage biopharmaceutical company developing innovative microRNA-targeting therapies to improve human health.

Gamida Cell is a biotechnology company developing cell therapies for treating cancer and hematologic diseases.

SiteOne Therapeutics is a Bozeman, Montana-based developer of products for therapeutics and diagnostics.

A biopharmaceutiical company discovering, developing and manufacturing therapeutics for the treatment of canccer

A company developing technologies in protein-based therapeutics

A biopharmaceutical company focused on the discovery and development of epigenetic medicines to treat cancer and other disease

A biotechnology company developing drugs for the treatment of metabolic diseases, cancer and inflammation

A biopharmaceutical company developing oral therapeutics for the treatment of mineral metabolism and metabolic disorders

A biotechnology company that develops therapeutic antibodies for treating infectious diseases and inflammation

A company that develops therapeutic oral medicines for the treatment of cancer and inflammatory diseases

A company designing bio-therapeutics for endocrine and other disorders

A biotechnology company developing peptides and antibodies for inflammation and autoimmunity

A consulting and research services company for science companies

Opsona Therapeutics is a Dublin-based company.

A biopharmaceutical company developing treatments for neuroendocrine, metabolic and immune disorders

A company developing cancer therapeutics

20 Results
Results per page:
Page 1 of 1

Acquisitions

Acquisition
Acquired company
Acquisition amount (USD)
Date announced
10,500,000,000
August 25, 2013
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Abid AZAM

Employee

Adam Hardin

Employee

Aditya Nag

Employee

aditya narula

Employee

Ahilaa Kamuthurai

Employee

AKASH ARYA

Employee

Alan Jamijian

Employee

Albert Hidayat

Employee

Alberto Chan

Employee

Alejandro Diaz

Employee

Alekhya Narni

Employee

Aleksander Malinowski

Employee

Alessandro Seveso

Employee

Alex Marzo

Employee

Alex Roman

Employee

Alex Shoshitaishvili

Employee

Alexander Julian Veach

Employee

Alfonso Kondo

Employee

Alfredo Zambonini

Employee

Alice Augustine

Employee

Alina Karimova

Employee

Alix Taffle

Employee

Allen Walker

Employee

Allison S

Employee

Alok Gandhi

Employee

Page 1 of 27
...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Heather McKenzie
May 3, 2021
BioSpace
BioSpace takes an in-depth look at the Top 25 of Q1.
May 3, 2021
BioSpace
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace
Karyopharm Therapeutics Inc.
May 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...
Annalee Armstrong
April 28, 2021
FierceBiotech
The pharma world is eagerly watching as Amgen moves its KRAS inhibitor toward a regulatory decision, and they now have a name for the much-anticipated new drug: Lumakras. Amgen listed off a laundry list of clinical trials and regulatory milestones for Lumakras while reporting first-quarter earnings April 27.
BioSpace
April 28, 2021
BioSpace
Amgen announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized clinical trial to compare the safety and efficacy of LUMAKRASTM at 960 mg once daily versus a lower daily dose of the drug.
Amgen
April 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the...
Amgen
April 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2021. Key results include: Total revenues decreased 4% to $5.9...
Amgen
April 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis...
April 23, 2021
BioSpace
National Kidney Foundation Appoints Alan C. Mendelson to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
National Kidney Foundation
April 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- The National Kidney Foundation (NKF) is pleased to announce the appointment of California businessman Alan C. Mendelson to its national Board...
Amgen
April 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the...
Alex Keown
April 21, 2021
BioSpace
The Swiss pharma giant quietly announced the cuts this morning in a breakdown of its first quarterly financial report.
Alex Keown
April 20, 2021
BioSpace
One month after snapping up Five Prime Therapeutics and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion, Amgen announced the U.S. FDA awarded Breakthrough Therapy Designation to the asset as a first-line treatment for certain types of gastric cancer.
April 20, 2021
BioSpace
Charles River Associates (CRA) Enhances Life Sciences Practice - read this article along with other careers information, tips and advice on BioSpace
Amgen
April 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for...
April 19, 2021
BioSpace
Amgen Launches Biomarker AssistTM, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing - read this article along with other careers information, tips and advice on BioSpace
BioSpace
April 19, 2021
BioSpace
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type.
Heather McKenzie
April 15, 2021
BioSpace
BGE-105 (formerly AMG 986) mimics the production of apelin, a peptide that has been found in animal studies to improve muscle regeneration and decrease mouse frailty.
Amirah Al Idrus
April 14, 2021
FierceBiotech
BioAge Labs is adding a third program to its pipeline. The new treatment, licensed from Amgen, is designed to combat muscle aging and could be useful in helping older people recover from surgery more quickly, decreasing muscle atrophy after a long hospital stay, or eventually, warding off frailty in older people.
BioSpace
April 13, 2021
BioSpace
Datos Health, a leader in remote care automation, today announced its collaboration with Amgen, one of the world's leading independent biotechnology companies, on a new study to evaluate the potential impact of digital health data to improve therapy in heart failure.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.